Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Update

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the recipient of a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 2,100 shares, a drop of 86.6% from the February 28th total of 15,700 shares. Based on an average daily volume of 100 shares, the short-interest ratio is currently 21.0 days. Approximately 0.0% of the company’s stock are sold short.

Basilea Pharmaceutica Price Performance

Shares of OTCMKTS:BPMUF remained flat at $54.00 during trading on Wednesday. The company’s 50-day moving average price is $52.90 and its 200-day moving average price is $52.59. Basilea Pharmaceutica has a one year low of $38.60 and a one year high of $54.00. The company has a debt-to-equity ratio of 5.70, a quick ratio of 3.27 and a current ratio of 4.10.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.